What does antibiotic resistance have to do with me?

Infections caused by resistant bacteria are associated with increased mortality and lower quality of life, because treatment is more difficult, often lasts longer, and is more expensive.

Anyone can catch an infection

GPs (general practitioners) as well as dentists, gynaecologists, dermatologists and many other specialists use antibiotic drugs for a wide range of bacterial infections, from less serious urinary tract infections to potentially life-threatening conditions such as pneumonia, meningitis or bacterial septicaemia. Anyone can catch an infection, which can be picked up during everyday life or in a hospital or healthcare facility. Infections can also appear after an accident or as a complication of a non-infectious disease.

Around one-third of all hospitalised patients in Switzerland receive antibiotics. This is necessary to prevent or treat infections linked to surgery or to complications of the disease for which the patient was initially hospitalised. Antibiotics are also frequently used to prevent infections in cancer patients undergoing chemotherapy. They enable organ transplants and treatments with immunosuppressants to provide relief in certain auto-immune conditions (e.g. rheumatoid arthritis or Crohn’s disease). They can also help treat complications of common conditions such as foot ulcers caused by diabetes.

Use of antibiotics with outpatients

Ambulanter Bereich
In outpatient (primary) care, antibiotics are used to treat the most common bacterial infections.

Use of antibiotics in hospitals

Bilder Spital Eingriffe Chemotherapie
In hospitals, antibiotics enable medical interventions that would have been very dangerous or inconceivable a hundred years ago: operations, organ transplants or chemotherapy for cancer.

Antibiotic resistance kills

According to new estimates, almost 1.3 million people around the world die each year from infections with resistant bacteria. On the basis of model calculations, the number of deaths in Switzerland is estimated at 300 per year, while this figure is 133,000 in Europe (WHO European Region).

Antibiotic resistance increases health costs

Infections due to antibiotic-resistant bacteria are among the most difficult to treat, and in rare cases they are not treatable at all, which is why expressions such as ‘super-bugs’ have been bandied about. Some of these resistant bacteria – fortunately not all of them – are more virulent for the human body – this means they are more likely to cause serious disease.

Infections caused by resistant bacteria are associated with increased mortality and lower quality of life, because treatment is more difficult, often lasts longer, and is more expensive. To treat such resistant infections, it is often necessary to resort to other classes of antibiotics, which are more expensive and may have more side effects or may need to be injected directly into the bloodstream.

At the global level, the economic impact of antibiotic resistance on health costs has been estimated at several billion US dollars per year. The World Bank has calculated that the annual costs of antibiotic resistance are comparable with the losses sustained in the financial crisis of 2008.

Why can’t we just develop new antibiotic drugs?

The extensive clinical trials that are required before a new antibiotic can be authorised and prescribed to patients take around ten years and are very costly. This is why Switzerland supports international initiatives to develop new antibiotics such as GARDP and national antibiotic research programmes such as the National Center of Competence in Research AntiResist.

However, new antibiotics are not enough to halt the spread of antibiotic-resistant bacteria. Above all, antibiotics must be used properly – particularly newly developed ones. Experience shows that bacteria develop resistance only a few years after a new class of antibiotic hits the market.

Data for when a drug is first marketed and when the first resistant bacte-ria are identified, for various classes of antibiotic. In some cases, resistant bacteria were observed before marketing even began. This was the case for the first antibiotic drug, penicillin, which was discovered in 1928 only launched on the market in 1940.
Source: Adapted from Antimicrobial Resistance and Infection Control (2015)

New classes of antibiotics: market launch and development of resistance.

Further information

NOSO Strategy: reduce Hospital and nursing home infections

With the NOSO Strategy, the Confederation and its implementation partners aim to better protect the population against hospital and nursing home infections. Here you can read about the measures that are implemented or planned.

Last modification 01.11.2023

Top of page


Federal Office of Public Health FOPH
Communicable Diseases Division
Strategies, Principles and Programmes Section
Schwarzenburgstrasse 157
3003 Bern
Tel. +41 58 463 87 06

Print contact